Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 11:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 939 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: PD-1 Clear all
Recruiting Phase 2 Interventional

Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer

NCT06959550
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Ivonescimab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 26, 2026, 11:32 PM EDT
Completed Phase 1Phase 2 Interventional

A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors

NCT02335918
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck (SCCHN), Ovarian Carcinoma-Enrollment Completed, Colorectal Cancer (CRC)-Enrollment Completed, Renal Cell Carcinoma (RCC) (Phase ll Only), Glioblastoma (GBM) (Phase ll Only)-Enrollment Completed
Interventions
Combination of varlilumab and nivolumab
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
19
States / cities
Tucson, Arizona • Palo Alto, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Oct 26, 2026, 11:32 PM EDT
Recruiting Phase 1 Interventional

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

NCT05422794
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Triple-Negative Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
Interventions
BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Nab-paclitaxel, Pembrolizumab
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Boston, Massachusetts • Mineola, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 26, 2026, 11:32 PM EDT
Completed Phase 2 Interventional

CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC

NCT04681131
View directory record Official record
Conditions
Non-Small-Cell Lung Cancer
Interventions
CAB-AXL-ADC, PD-1 inhibitor
Biological
Lead sponsor
BioAtla, Inc.
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
32
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 26, 2026, 11:32 PM EDT
Recruiting Phase 2 Interventional

Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma

NCT06161545
View directory record Official record
Conditions
Stage II Squamous Cell Carcinoma of the Head and Neck, Stage III Squamous Cell Carcinoma of the Head and Neck, Stage IV Squamous Cell Carcinoma of the Head and Neck
Interventions
PD-L1 t-haNK cells, pembrolizumab, N-803
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 26, 2026, 11:32 PM EDT
Completed Phase 2 Interventional Results available

Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma

NCT04493203
View directory record Official record
Conditions
Advanced Melanoma, Unresectable Melanoma
Interventions
Nivolumab, Axitinib
Drug
Lead sponsor
Yana Najjar
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Oct 26, 2026, 11:32 PM EDT
Completed Phase 4 Interventional Results available

A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10)

NCT04489888
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
Pembrolizumab, Carboplatin, Paclitaxel
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
14
States / cities
New Haven, Connecticut • Newark, Delaware • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2025 · Synced Oct 26, 2026, 11:32 PM EDT
Recruiting Phase 2 Interventional

Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)

NCT06228066
View directory record Official record
Conditions
Small Cell Carcinoma of the Bladder, High Grade Neuroendocrine Tumors of the Urinary Tract
Interventions
Lurbinectedin, Avelumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 26, 2026, 11:32 PM EDT
Terminated Phase 1 Interventional

FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

NCT05069935
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
FT538, Cyclophosphamide, Fludarabine, Monoclonal antibody - Dose Escalation, Monoclonal antibody - Dose Expansion
Drug · Combination Product
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Hackensack, New Jersey • Nashville, Tennessee • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 26, 2026, 11:32 PM EDT
Active, not recruiting Phase 2 Interventional

A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

NCT06190951
View directory record Official record
Conditions
Melanoma
Interventions
cemiplimab, Fixed Dose Combination (FDC) cemiplimab+fianlimab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
28
States / cities
La Jolla, California • Los Angeles, California • Newport Beach, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 26, 2026, 11:32 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy

NCT02971748
View directory record Official record
Conditions
Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Breast Inflammatory Carcinoma, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions
Pembrolizumab
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 26, 2026, 11:32 PM EDT
Completed Phase 1 Interventional

CART-EGFRvIII + Pembrolizumab in GBM

NCT03726515
View directory record Official record
Conditions
Glioblastoma
Interventions
CART-EGFRvIII T cells, Pembrolizumab
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 26, 2026, 11:32 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma

NCT02423343
View directory record Official record
Conditions
Solid Tumor, Non-Small Cell Lung Cancer Recurrent, Hepatocellular Carcinoma Recurrent
Interventions
Galunisertib, Nivolumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
5
States / cities
Birmingham, Alabama • La Jolla, California • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2021 · Synced Oct 26, 2026, 11:32 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma

NCT04139902
View directory record Official record
Conditions
Melanoma Stage III, Melanoma Stage IV
Interventions
Dostarlimab (TSR-042) (singly), Dostarlimab (TSR-042) and TSR-022 (combination)
Drug
Lead sponsor
Diwakar Davar
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 26, 2026, 11:32 PM EDT
Recruiting Phase 2 Interventional

Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma

NCT05496036
View directory record Official record
Conditions
Merkel Cell Carcinoma
Interventions
Pembrolizumab
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 26, 2026, 11:32 PM EDT
Terminated Phase 2 Interventional Results available

Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer

NCT01420965
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
CT-011 (Anti-PD1 Antibody), Sipuleucel-T (Provenge), Cyclophosphamide
Drug · Other
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Oct 26, 2026, 11:32 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy

NCT02411656
View directory record Official record
Conditions
Edema, Erythema, Estrogen Receptor Negative, HER2/Neu Negative, Peau d'Orange, Progesterone Receptor Negative, Recurrent Inflammatory Breast Carcinoma, Stage IV Inflammatory Breast Carcinoma, Triple-Negative Breast Carcinoma
Interventions
Laboratory Biomarker Analysis, Pembrolizumab
Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 26, 2026, 11:32 PM EDT
Completed Phase 1Phase 2 Interventional Results available

M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers

NCT03554473
View directory record Official record
Conditions
Carcinoma, Small Cell, Lung Cancer, Small Cell Lung Cancer
Interventions
M7824, Topotecan, Temozolomide, EKG, CT scan, PET scan, Acetaminophen, Antihistamines, Diphenhydramine, Dexamethasone, Epinephrine
Drug · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 26, 2026, 11:32 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).

NCT04895722
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Pembrolizumab, Pembrolizumab/Quavonlimab, Pembrolizumab/Favezelimab, Pembrolizumab/Vibostolimab, MK-4830
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
11
States / cities
Orange City, Florida • Athens, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 26, 2026, 11:32 PM EDT
Completed Phase 1 Interventional Results available

Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

NCT03239145
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
Pembrolizumab, Trebananib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 26, 2026, 11:32 PM EDT
Completed Phase 1 Interventional

Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies

NCT02383212
View directory record Official record
Conditions
Advanced Cancer, Advanced Malignancies
Interventions
Cemiplimab, Hypofractionated radiotherapy, Cyclophosphamide, Docetaxel, Carboplatin, GM-CSF, Paclitaxel, Pemetrexed
Drug · Radiation
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
40
States / cities
Gilbert, Arizona • Goodyear, Arizona • Phoenix, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 26, 2026, 11:32 PM EDT
Terminated Phase 3 Interventional Results available

Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)

NCT03833167
View directory record Official record
Conditions
Carcinoma, Squamous Cell
Interventions
Pembrolizumab, Placebo
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
30
States / cities
Mobile, Alabama • Duarte, California • La Jolla, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 26, 2026, 11:32 PM EDT
Recruiting Phase 1 Interventional

A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC

NCT06826768
View directory record Official record
Conditions
Prostate Cancer
Interventions
REGN5678, Cemiplimab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 26, 2026, 11:32 PM EDT
Completed Phase 1 Interventional

Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy

NCT04635995
View directory record Official record
Conditions
Cancer
Interventions
LVGN7409
Biological
Lead sponsor
Lyvgen Biopharma Holdings Limited
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 26, 2026, 11:32 PM EDT